Intriguingly, this patient did not harbour any mutation or gene copy variation in PTEN, PIK3CA, PIK3CB or AKT2. As we are writing this review, other clinical trials are currently recruiting patients with advanced solid tumours harbouring PTEN loss or with PIK3CB mutation and/or amplification and may include patients with endometrial cancer (Table 2). This evidence concerns the gene PIK3CA and endometrial cancer.